The research, published in BMC Cancer by Lei Wang of Chongqing University Three Gorges Hospital, Hao Sun of the Second Affiliated Hospital of Shandong First Medical University and Taizhou People’s Hospital, and colleagues, examined a question that sits at the intersection of oncology and nephrology, a field sometimes called onco-nephrology. Clinicians can estimate filtration rate from serum creatinine, a muscle-derived waste product, or from cystatin C, a small protein produced steadily by nearly all nucleated cells. Because creatinine levels are influenced by muscle mass, diet, and other non-kidney factors, while cystatin C is thought to be less dependent on body composition, the two markers can yield different answers. When the cystatin C-based estimate falls substantially below the creatinine-based one, a situation researchers call large negative discordance, it may flag hidden kidney impairment that the creatinine number alone would miss.

Whether a history of cancer makes such discordance more likely had remained unclear. Cancer and its treatments can reshape body composition, deplete muscle, and alter inflammation, all of which can perturb creatinine independently of true filtration capacity. At the same time, some malignancies and therapies may affect cystatin C production or clearance. The Chinese team set out to quantify the association in a real-world screening population rather than in hospitalized patients, drawing on adults who attended single-visit health examinations with linked questionnaire data at centers in Chongqing, Shandong, and Jiangsu between January and July 2026.

The analytic cohort was deliberately restricted to people whose kidneys looked healthy by the usual screening standard: participants needed both a creatinine and a cystatin C measurement, an ascertainable cancer history, complete covariate data, plausible laboratory values, and a creatinine-based eGFR of at least 60 milliliters per minute per 1.73 square meters, the conventional threshold below which chronic kidney disease is generally staged. The investigators recalculated eGFR from the original measurements using creatinine alone, cystatin C alone, and both markers together. The primary outcome, large negative discordance, was defined as a cystatin C-based estimate at least 30 percent lower than the creatinine-based estimate. Prevalence ratios were estimated with modified Poisson regression using robust variance, and the team layered on an unusually thorough set of sensitivity analyses: center-specific and pooled models, alternative discordance definitions, continuous differences between the estimates, migration across GFR categories, subgroup analyses, overlap weighting, and an age-spline analysis.

Among 3,491 participants, 257, or 7.36 percent, reported a physician-diagnosed history of cancer. The headline finding was stark at the crude level: large negative discordance occurred in 14.79 percent of participants with a cancer history compared with 4.79 percent of those without, a difference the authors report as statistically significant with a P value below 0.001. In other words, roughly one in seven cancer survivors whose creatinine-based estimate suggested preserved kidney function had a cystatin C-based estimate at least 30 percent lower, a pattern seen in fewer than one in twenty of their cancer-free counterparts.

Adjustment for other characteristics softened but did not erase the signal. In the fully adjusted pooled model, cancer history remained associated with a higher prevalence of large negative discordance, with a prevalence ratio of 1.53 and a 95 percent confidence interval of 1.08 to 2.17, corresponding to a P value of 0.018. The association was also visible on a continuous scale: cancer history was linked to an adjusted relative eGFR difference that was 2.73 percentage points lower, with a confidence interval spanning -4.46 to -1.00 and a P value of 0.002. When the team relaxed the discordance threshold to 20 percent or used an absolute difference of -15 milliliters per minute per 1.73 square meters, similar patterns emerged, lending the result a degree of robustness across how the phenomenon is defined.

The geographic texture of the data, however, complicates any simple interpretation. When Chongqing and Shandong were combined, the adjusted prevalence ratio was 1.22 with a confidence interval of 0.78 to 1.89 and a P value of 0.383, meaning the association was not statistically distinguishable from no association at those two centers. In Jiangsu, by contrast, the prevalence ratio climbed to 2.40 with a confidence interval of 1.37 to 4.18 and a P value of 0.002, a substantially stronger effect. The formal test for a center-by-cancer-history interaction was not significant, with a P value of 0.212, but the authors are careful to warn that this nonsignificant interaction should not be read as proof that the effect is equivalent across centers. Absence of a statistically significant interaction is not the same as presence of equivalence, particularly in a cohort of this size.

Not every analytic approach supported the association. Crude downward migration across GFR categories, in which participants appeared to shift into a worse kidney-function category when cystatin C was used instead of creatinine, was substantially attenuated after multivariable adjustment, and the overlap-weighted and adjusted category-migration analyses were described as less precise or null. The authors are explicit about the limits of their design: this is a cross-sectional study, so it cannot establish that cancer or its treatments cause the discordance, nor can it determine which of the two estimates is closer to a directly measured glomerular filtration rate. The study also cannot establish that participants with discordant estimates actually had impaired kidney function; it shows only that the two markers disagreed more often in people with a cancer history.

Why might cancer survivors show this pattern? The study itself does not identify a mechanism, but the biology offers plausible candidates. Creatinine is generated by muscle, and cancer survivors frequently have reduced muscle mass due to the disease, its treatments, or lifestyle changes, which would lower creatinine and inflate the creatinine-based eGFR, making it look as though the kidneys are filtering better than they are. Cystatin C, meanwhile, is less tied to muscle but can be influenced by inflammation, thyroid function, obesity, and possibly malignancy itself. If cancer history shifts the balance of these non-GFR determinants, the two formulas would part ways more often. Disentangling which marker, if either, is telling the truth in this population would require studies comparing both estimates against measured GFR using tracer or clearance methods, which this study did not perform.

The practical takeaway, according to the authors, is one of caution rather than alarm. Among adults with a creatinine-based eGFR of 60 or above attending routine health examinations at three Chinese centers, cancer history was associated with greater negative discordance between the cystatin C- and creatinine-based estimates in the pooled adjusted analysis, with estimates varying across centers. When a kidney-function estimate is clinically consequential, for example when it will guide drug dosing, contrast imaging decisions, or nephrology referral in an adult with a history of cancer, the findings suggest that relying on a single filtration marker should be done cautiously. Measuring both creatinine and cystatin C, or confirming an uncertain estimate with a direct measurement of filtration rate, may be prudent in exactly the situations where the number will change management. As cancer survival continues to improve worldwide and the population of long-term survivors grows, the humble eGFR calculation, and the assumptions baked into it, may deserve closer scrutiny than a single number on a lab report usually receives.

Subject of Research: Association between cancer history and discordance between creatinine- and cystatin C-based estimated glomerular filtration rate in health-examination adults

Article Title: Cancer history and creatinine-cystatin C eGFR discordance across three Chinese health-examination centers

Article References: Wang, L., Sun, H., Yao, X., Xiang, H., Tan, H., Wei, D., & Gong, X. (2026). Cancer history and creatinine-cystatin C eGFR discordance across three Chinese health-examination centers. BMC Cancer. https://doi.org/10.1186/s12885-026-16998-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16998-w

Keywords: cancer history, cystatin C, creatinine, eGFR discordance, estimated glomerular filtration rate, kidney function, onco-nephrology, cross-sectional study, chronic kidney disease, health examination, China, BMC Cancer

The study, published in Supportive Care in Cancer, was led by Syed E. Pasha of the University of Houston and HCA Houston Healthcare Kingwood, together with colleagues from MountainView Hospital and Texas Oncology centers. The team set out to answer a deceptively simple question: do patients with diffuse large B-cell lymphoma, an aggressive and rapidly treated lymphoma, experience different kidney outcomes than patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, an indolent disease that often smolders for years before requiring therapy? Comparative renal data between these two populations had been scarce, despite the fact that both cancers are common and both are treated with regimens known to stress the kidneys.

To answer the question, the researchers turned to the TriNetX Global Collaborative Network, a federated database drawing de-identified electronic health records from 143 healthcare organizations. Data were extracted on May 9, 2025. Adults with a coded diagnosis of diffuse large B-cell lymphoma or of chronic lymphocytic leukemia and small lymphocytic lymphoma were identified using standard ICD-10 diagnostic codes. To make the two groups as comparable as possible, the investigators used a statistical technique called propensity score matching, pairing each patient with a counterpart from the other cohort who shared the same age, sex, race, and ethnicity. This one-to-one matching produced two demographically indistinguishable groups, with standardized mean differences between them ranging from just 0.001 to 0.038, values so small they indicate near-perfect balance.

The final analysis included 19,438 patients, evenly split with 9,719 in each cohort. Kidney outcomes were tracked from the first day after the index diagnosis through each patient’s available follow-up, an open-ended window rather than a fixed observation period. The researchers looked for two distinct conditions: acute kidney injury, the sudden loss of renal function that can develop within hours or days, and chronic kidney disease, the gradual, often irreversible decline in filtration capacity that unfolds over months and years. Statistical comparisons relied on two-proportion z-tests, generating risk differences, risk ratios, and odds ratios with 95 percent confidence intervals.

The results revealed a fascinating split. Acute kidney injury struck 22.9 percent of the diffuse large B-cell lymphoma patients compared with 20.9 percent of the chronic lymphocytic leukemia and small lymphocytic lymphoma group. That two-percentage-point gap was statistically significant, with a risk ratio of 1.094 and an odds ratio of 1.122, and a p-value of 0.001. In other words, the aggressive lymphoma carried a modestly higher risk of sudden renal failure. The pattern flipped for chronic kidney disease. Here, 18.8 percent of the lymphoma patients developed the condition versus 22.7 percent of the leukemia and indolent lymphoma group, a negative risk difference of 4.0 percent, with a risk ratio of 0.825 and an odds ratio of 0.785, and a p-value below 0.001. The slower cancer, paradoxically, left a heavier mark on long-term kidney health.

The biology behind this divergence makes intuitive sense when one considers how each disease and its treatment unfold. Diffuse large B-cell lymphoma grows quickly and is typically treated with intensive chemoimmunotherapy, most commonly regimens built around rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone. Rapid tumor cell death can trigger tumor lysis syndrome, a cascade in which potassium, phosphate, and uric acid flood the bloodstream and crystallize in renal tubules, a well-documented cause of acute kidney injury. High-dose chemotherapy agents themselves, along with the infections, dehydration, and intensive care admissions that can accompany aggressive treatment, all add to the short-term renal assault.

Chronic lymphocytic leukemia, by contrast, is a disease of accumulation and time. Patients frequently live with it for a decade or more, and even those who never require treatment face aging kidneys, cumulative exposure to nephrotoxic drugs across successive lines of therapy, and immune complications. Modern targeted therapies such as ibrutinib, which has transformed outcomes in this disease, carry their own renal baggage; real-world analyses of hundreds of treated patients have documented a spectrum of toxicities that can include hypertension and kidney dysfunction. Over years of surveillance, treatment, and comorbidity, the indolent disease’s patient population gradually accrues the chronic damage that shows up as chronic kidney disease. The new data, showing a 22.7 percent chronic kidney disease rate in this group, align with that clinical picture.

The authors are careful to frame their findings as hypothesis-generating rather than definitive. The matching algorithm balanced demographics but did not capture comorbidities such as diabetes, hypertension, or pre-existing renal impairment, all of which are powerful drivers of kidney disease and may differ systematically between the two cancer populations. Follow-up duration was also not matched, and the open-ended observation window means patients in one group may simply have been watched longer. Absolute differences between the cohorts were small, in the range of two to four percentage points, and the study relied on administrative diagnostic codes rather than laboratory-verified kidney function measures. The research was supported in whole or in part by HCA Healthcare, though the authors declare no competing interests, and the views expressed are those of the authors alone.

Even with those caveats, the study carries practical weight for the growing field of onco-nephrology, the discipline that sits at the intersection of cancer care and kidney medicine. Acute kidney injury in patients with hematological malignancies is known to worsen remission rates and survival, and chronic kidney disease constrains which cancer therapies a patient can safely receive, since many agents require dose adjustment or are contraindicated in renal impairment. If the pattern observed here holds up, supportive care pathways might reasonably emphasize vigilant short-term renal monitoring, hydration protocols, and uric acid management around the intensive treatment phases of aggressive lymphoma, while building durable long-term nephrology follow-up into the care of chronic lymphocytic leukemia survivors, whose kidneys face a marathon rather than a sprint.

What comes next is confirmation. The authors themselves call for comorbidity-adjusted analyses and prospective studies to verify whether the renal risk differences survive when diabetes, hypertension, baseline kidney function, and treatment exposure are properly accounted for. Until then, the message for clinicians is one of heightened awareness rather than alarm: both cancer subtypes deserve deliberate attention to the kidneys, but the timing and nature of that attention may need to differ. A single dataset of nearly twenty thousand matched patients cannot settle every question, but it has usefully drawn a map, pointing oncologists toward the moments in each disease trajectory where the kidneys are most vulnerable, and reminding the wider medical community that surviving cancer is only half the story, with protecting the organs that carry patients through survivorship being the other half.

Subject of Research: Comparative renal outcomes of acute kidney injury and chronic kidney disease in diffuse large B-cell lymphoma versus chronic lymphocytic leukemia/small lymphocytic lymphoma

Article Title: Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care

Article References: Pasha, S. E., Khalique, S., Haddadin, R., Mazharuddin, S., & Khoury, P. N. (2026). Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care. Supportive Care in Cancer, 34(10), Article 1029. https://doi.org/10.1007/s00520-026-11256-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11256-y

Keywords: diffuse large B-cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, acute kidney injury, chronic kidney disease, supportive oncology, onco-nephrology, nephrotoxicity, TriNetX, propensity score matching, real-world data, tumor lysis syndrome

The scale of the problem is substantial. As survival from cancer lengthens and treatment regimens grow more intense, kidney injury has emerged as a major clinical issue that can compromise both prognosis and quality of life. The review, led by Zixuan Chen and colleagues at Tongren Hospital, Shanghai Jiao Tong University School of Medicine, together with Hua Sun at the University of Iowa, catalogs how nearly every major class of anticancer therapy inflicts a distinct pattern of renal damage. Conventional chemotherapeutics, molecular targeted agents, immune checkpoint inhibitors, and immune cell therapies each attack the kidney through different biological routes, making ATRI not a single disease but a family of injuries requiring tailored solutions.

Cisplatin, a cornerstone of chemotherapy for decades, remains one of the most notorious offenders. The drug accumulates preferentially in renal proximal tubular epithelial cells, partly through the organic cation transporter 2, where it triggers oxidative stress, mitochondrial dysfunction, and tubular apoptosis. Even with standard preventive measures such as hydration, cisplatin-associated acute kidney injury remains clinically common, and when poorly managed it can progress to renal fibrosis and chronic kidney disease. Molecular targeted drugs behave differently. Inhibitors of the vascular endothelial growth factor pathway frequently cause proteinuria and hypertension by disrupting the delicate crosstalk between podocytes and glomerular endothelial cells, sometimes culminating in thrombotic microangiopathy. Fibroblast growth factor receptor inhibitors produce a strikingly different signature: hyperphosphatemia occurs in roughly 60 to 70 percent of patients, reflecting interference with the FGF23-FGFR axis and impaired renal phosphate handling.

The immunotherapy era has added entirely new injury patterns. Immune checkpoint inhibitors, by dismantling peripheral immune tolerance, can provoke T-cell attacks on renal antigens, most commonly manifesting as acute interstitial nephritis with an estimated incidence of 3 to 5 percent. Recent multicenter work incorporating immunophenotyping suggests these nephritides may include separable inflammatory subtypes that respond differently to glucocorticoids, underscoring the need for precision classification. Meanwhile, chimeric antigen receptor T-cell therapy introduces kidney injury through an even more circuitous route. Acute kidney injury after CAR-T therapy occurs in roughly 5 to 33 percent of patients, with a pooled incidence of about 19 percent, driven largely by cytokine release syndrome, capillary leak, hemodynamic instability, and tumor lysis rather than direct drug toxicity.

Current management of all these injuries is largely reactive. Clinicians rely on monitoring serum creatinine, adjusting doses, pausing treatment, or administering steroids when immune-mediated nephritis appears. Each approach carries a cost. Serum creatinine is a lagging indicator that can miss early tubular injury, and dose reduction, while often the most effective nephroprotective move, may compromise antitumor efficacy and limit regimen intensity. As combination regimens integrating chemotherapy, targeted therapy, immunotherapy, and cellular immunotherapy become standard, overlapping injury pathways and drug interactions are stretching current management paradigms to their limits. What is missing, the authors argue, is a strategy that actively preserves nephron structure and function without interfering with cancer treatment.

Enter mesenchymal stem cells, or MSCs, the most widely studied cell type in translational kidney protection. Rather than differentiating into renal parenchymal cells, MSCs act mainly as mobile secretory units, sensing tissue injury cues and releasing bioactive factors and extracellular vesicles that reshape the local microenvironment. Their renoprotective repertoire spans three dimensions. They secrete anti-inflammatory mediators such as TSG-6, prostaglandin E2, and interleukin-10 that dampen excessive immune activation. They release trophic factors including hepatocyte growth factor and VEGF that reduce tubular cell apoptosis, and in one particularly striking mechanism they deliver functional mitochondria to injured tubular cells through tunneling nanotubes, rapidly restoring bioenergetic capacity. They also suppress profibrotic signaling through the TGF-beta1 and Smad axis, limiting the scarring that follows sustained injury. These properties map most directly onto cisplatin-associated nephrotoxicity, where tubular stress, oxidative damage, and mitochondrial dysfunction dominate.

Yet MSCs face two formidable barriers in oncology. The first is delivery: after systemic infusion, only a small fraction of administered cells reach and persist within the kidney, constraining efficacy and increasing variability. Image-guided regional administration has shown promise in preclinical studies but remains unstandardized. The second, and thornier, barrier is oncologic safety. Because MSCs modulate immune responses and promote angiogenic signaling, their influence on the tumor microenvironment is a genuine theoretical concern, and the nature of that concern shifts with treatment context. In patients receiving checkpoint inhibitors, MSC immunoregulation might either resolve renal immune toxicity or blunt checkpoint efficacy. In those on VEGF pathway inhibitors, pro-angiogenic signals could theoretically counteract the antitumor mechanism itself. The authors suggest that acceptable risk may differ between curative-intent and palliative settings, with a more permissive calculus justified when renal preservation directly determines treatment continuity.

Renal progenitor and precursor cells represent a fundamentally different reparative philosophy: instead of modulating inflammation, they aim to replace lost epithelial cells and reconstruct nephron structure. Advances in induced pluripotent stem cell technology have enabled the generation of human iPSC-derived nephron progenitor cells expressing developmental markers such as SIX2 and WT1, capable of differentiating toward podocyte-like and tubular epithelial phenotypes. In mouse models of cisplatin-induced injury, transplanted progenitors localize to damaged regions, contribute to epithelial repair, and secrete trophic factors supporting recovery. Urine-derived precursor-like cells expressing SOX9-related programs offer a noninvasive, autologous sourcing route that sidesteps immune rejection. But the bar for clinical implementation is high: stringent control of cell purity, differentiation stage, genomic stability, and non-tumorigenicity is essential, particularly because chemotherapy and targeted therapies impose genotoxic pressures that could destabilize transplanted cells.

Exosomes, nanoscale vesicles carrying proteins, nucleic acids, and lipids, are emerging as the leading cell-free alternative. MSC-derived exosomes recapitulate many benefits of their parent cells while avoiding risks of live-cell administration such as microvascular trapping and uncontrolled proliferation. Their phospholipid bilayer protects cargo, their small size and low immunogenicity favor systemic delivery, and the absence of a complete cellular genome substantially reduces proliferation concerns. Exosomal microRNAs can modulate apoptosis and inflammatory signaling in recipient renal cells, while antioxidant enzymes mitigate reactive oxygen species. Yet the review issues a clear warning: exosomes are not inherently safer. Tumor-derived exosomes can promote immune evasion and therapeutic resistance, with reports in renal cell carcinoma showing that exosomes from drug-resistant cells carry elevated PD-L1. Even MSC-derived exosomes may carry pro-angiogenic or therapy-resistance-promoting cargo depending on source cell state and manufacturing conditions. Rigorous cargo profiling, standardized characterization under MISEV2023 guidance, and validation in tumor-bearing models are prerequisites before clinical advancement.

The path forward, the authors conclude, requires coordinated advances across engineering, delivery, clinical stratification, trial design, and manufacturing. Future cell products will likely be bioengineered rather than unmodified, with gene editing and controlled preconditioning creating context-responsive cells activated only within injured renal tissue. Kidney organoids are poised to become a transformative testing platform, recapitulating human renal injury in vitro and enabling higher-throughput screening of protective interventions. Clinically, the field must shift from reactive rescue to proactive, risk-adapted nephroprotection guided by novel biomarkers and integrated prediction models, and trials must adopt durable endpoints such as one-year estimated glomerular filtration rate slope and chronic kidney disease progression rather than short-term creatinine changes. For now, cell-based and cell-derived therapies remain emerging translational candidates rather than established treatments, but they offer something oncology has lacked: a conceptual framework for protecting the kidney without surrendering the cure.

Subject of Research: Cell-based and cell-derived renoprotective strategies for kidney injury caused by anticancer therapies

Article Title: Cell-based and cell-derived strategies for anticancer therapy-related renal injury: progress, challenges, and translational perspectives

Article References: Chen, Z., Xie, Y., Sun, H., & Liu, M. (2026). Cell-based and cell-derived strategies for anticancer therapy-related renal injury: progress, challenges, and translational perspectives. Holistic Integrative Oncology, 5(1), Article 61. https://doi.org/10.1007/s44178-026-00284-7

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00284-7

Keywords: onco-nephrology, acute kidney injury, mesenchymal stem cells, exosomes, renal progenitor cells, cisplatin nephrotoxicity, immune checkpoint inhibitors, CAR-T therapy, kidney organoids, cell therapy, renal fibrosis, extracellular vesicles